Skip to main content
MTRI
NASDAQ Life Sciences

Mentari Replaces Both Legacy Auditors with Deloitte Days After Merger Close

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$15.245
Mkt Cap
$807.261M
52W Low
$12.2
52W High
$233
52W Position info
25% above low
Off High info
93% below high
Rel. Volume info
1.6× avg
Market data snapshot near publication time

MTRI sits 25% above its 52-week low of $12.2.

Summary

Three days after its merger closed, Mentari dismissed both CBIZ and EY as auditors and engaged Deloitte for fiscal 2026. Both predecessor reports carried going-concern warnings, and the company had already reported a $63.0 million nine-month net loss.


Key Events · Corporate Governance and Compliance · MTRI

  • Both Legacy Auditors Dismissed

    With Audit Committee approval, CBIZ CPAs P.C. (InMed's auditor) and Ernst & Young LLP (Mentari's auditor) were both dismissed on November 17, 2026.

  • Deloitte Engaged for Fiscal 2026

    Deloitte & Touche LLP was engaged on November 19, 2026, as the combined company's independent registered public accounting firm for the year ending December 31, 2026.

  • Going-Concern Warnings in Both Reports

    Each predecessor report — CBIZ's on InMed and EY's on Mentari — contained an explanatory paragraph stating substantial doubt about the entity's ability to continue as a going concern.

  • Clean Dismissals, No Disagreements

    The filing states there were no disagreements on accounting principles or practices and no reportable events with either predecessor firm through November 17, 2026.


Analysis · MTRI · Life Sciences

Three days after closing its reverse merger with InMed, Mentari dismissed both legacy audit firms — CBIZ, InMed's auditor, and EY, Mentari's auditor — and engaged Deloitte for fiscal 2026. The dismissals themselves are clean: no disagreements and no reportable events for either firm. The going-concern language is what matters. Both CBIZ's report on InMed and EY's report on Mentari carried explanatory paragraphs stating substantial doubt about each entity's ability to continue as a going concern. That is a survival question for the combined company, not a housekeeping item, and it lands alongside the $63.0 million nine-month net loss disclosed in the November 16 8-K. Deloitte inherits a first-year audit of a freshly merged, loss-making biotech with a going-concern history — a heavier lift than a routine re-appointment, and one investors should read as a real balance-sheet warning rather than a formality.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MTRI was trading at $15.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $807.3M. The 52-week trading range was $12.20 to $233.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MTRI - Latest Insights

MTRI
Nov 16, 2026, 7:03 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.00
Real-time Price: $15.25 info
Change: -$3.76 (-20%) info
Market Cap: $807.261M info